Navigation Links
Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus

CAMBRIDGE, Mass., Aug. 31, 2015 /PRNewswire/ -- Daktari Diagnostics today announced a collaboration with Merck, known as MSD outside the United States and Canada, to develop Daktari's rapid hepatitis C virus (HCV) screening test. The deal, worth up to $8.5 million over the next 3.5 years, will support an accelerated development timeline for the clinical validation and regulatory approval of Daktari's HCV test.

The Daktari technology forms the basis for a point-of-care instrument that can detect low levels of virus directly in a single drop of blood in approximately 30 minutes, making on-the-spot HCV treatment decisions possible. The Daktari test is based on high-sensitivity measurement of the HCV core antigen, which is used in Europe and Japan for the diagnosis of chronic hepatitis C infection, but has never been available as a point-of-care diagnostic.

The Daktari™ System includes an embedded connectivity platform, Daktari InSight, which provides real-time data management through mobile network connectivity and a web-based dashboard, allowing rapid monitoring of test results. The Daktari™ System has the potential to transform public health screening programs and be made available at retail clinics, pharmacies, and doctor's offices.

"For many patients chronic hepatitis C has become a curable disease," said Bill Rodriguez, M.D., Founder and CEO of Daktari.  "Merck's collaboration provides support for an accelerated development and regulatory timeline for our HCV diagnostic."

Globally, HCV is "severely underdiagnosed".1  Some 130 to 150 million people are infected with chronic HCV worldwide, including 2.7 million people in the United States, but fewer than 2 percent are aware of their infection. Simpler screening tests are expected to greatly expand diagnosis of individuals infected with HCV who need treatment. The World Health Organization recommends that HCV testing be offered in settings of high HCV prevalence or to people at risk for HCV.2 In the United States, the Centers for Disease Control and the U.S. Preventive Services Task Force (USPTF) both recommended HCV testing for all adults born between 1945 and 1965, regardless of risk, and persons of all ages who are at risk for HCV infection.3

About Daktari

Daktari Diagnostics, Inc. ( is a venture-backed company based in Cambridge, USA. Daktari's mission is to address the world's biggest health problems through a new generation of simple, affordable molecular diagnostic tests that can be deployed anywhere in the world. The Daktari connectivity platform, Daktari InSight, provides real-time data management through mobile network connectivity and a web-based dashboard, allowing instantaneous monitoring of test results and disease outbreaks from any health facility in the world.  In addition to hepatitis C, HIV, and other infectious diseases, Daktari is developing cardiology and hematology tests for use in doctor's offices and emergency rooms.


1.      Denkinger CM and Kessel M. Diagnostics for hepatitis C: An urgent need for action. The Lancet Global Health 2015; 3(4), pp. 195.

2.     World Health Organization.

3.    Centers for Disease Control and Prevention.

Media Contact

Tiana Veldwisch 
+1 (617) 336-3299

SOURCE Daktari Diagnostics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Daktari Accepted into WHO Prequalification of Diagnostics Programme
2. Daktari Honored with IEEE Spectrum Award
3. Endexx Enters Into Definitive Agreement to Acquire Dispense Labs, LLC
4. BioDrain Breaks into National Network of Ambulatory Surgical Centers and Expands Installations of its STREAMWAY System throughout the U.S.
5. Neurelis Enters into Option and Merger Agreement with Biotie Therapies
6. A Finnish Company Enters International Markets With World Class Genetics Technology
7. U.S. News & World Report Honors 7 SynCardia Certified Centers Among "Best Childrens Hospitals" for Cardiology and Heart Surgery
8. Queen Emma Land Company and Taubman Centers Announce Saks Fifth Avenue to Anchor the Revitalized International Market Place
9. Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities
10. Parent Project Muscular Dystrophy Returns to Baltimore for Annual Connect Conference; Presenters Include FDA, Major Pharma
11. ChemOutsourcing Announces 30 Pharma Company Presenters for September 2013 Outsourcing Show in New Jersey
Post Your Comments:
(Date:9/17/2019)... (PRWEB) , ... September 18, 2019 , ... Uniform ... Beyond Breast Cancer to raise funds for Breast Cancer programs and services. , This ... 42,000 will die of the disease. During the month of October 2019, Uniform Advantage ...
(Date:9/17/2019)... HILL, N.J. (PRWEB) , ... September 17, 2019 ... ... Canal Calem Periodontics located in Moorestown and Medford, NJ, now welcome patients from ... of periodontists strives to save natural teeth whenever possible. When tooth removal is ...
(Date:9/17/2019)... ... ... Embr Labs , the breakthrough thermal technology company and creator of ... Partners, with participation from Safar Partners, Joyance Partners , Bose Ventures ... footprint in wellness and digital therapeutics, accelerate development for the next generation of its ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... September 17, 2019 , ... ... Keflezighi and the American Heart Association (AHA)-San Diego Chapter to raise awareness of ... Stroke Walk on Saturday, September 21 in Balboa Park alongside National University System ...
(Date:9/17/2019)... ... 2019 , ... Drs. Charles Felts and Elizabeth Felts Randall ... TN for customized full mouth dental implants with TeethXpress® . TeethXpress treatment ... a permanent tooth replacement solution for patients who struggle with the pain and ...
(Date:9/17/2019)... ... September 17, 2019 , ... Specialty Technical ... updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Japan . ... scope of their EHS regulatory obligations and rapidly collect, share, archive, and export ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... on the detection and treatment of infectious diseases at its annual Congress ... were noninvasive detection of residual HIV infected cell persistence and the development ...
(Date:9/11/2019)... ... ... A September 2 article on CBS News details a new ... to suffer heart attacks, strokes, kidney failure, and heart disease versus a control group ... specialists Dr. Feiz and Associates says the study adds further evidence to an overwhelming ...
Breaking Medicine News(10 mins):